Colgate-Palmolive Company

(New York Stock Exchange)
Back to all articles
Bullish +60

Clorox vs. Colgate: One Pays Nearly 6%, but Is It a Dividend Trap?

Dividend AI-generated analysis

πŸ“‰ Clorox's stock price fell 22% over the past year, causing its dividend yield to expand artificially from a lower base.

πŸ’Έ Clorox's operating cash flow dropped 38% to $612M in fiscal 2026, raising concerns about the ability to sustain its $5.00 annual dividend.

πŸ“‰ Clorox's fourth-quarter gross margin contracted significantly to 41.3%, down 520 basis points from the prior year.

πŸ’° Colgate-Palmolive generated $3.6B in free cash flow in 2025, providing a strong buffer for shareholder returns.

πŸ“ˆ Colgate has raised its dividend for 63 consecutive years, establishing itself as a Dividend Aristocrat with a long-term safety record.

πŸ›‘οΈ Colgate-Palmolive's Base Business EPS growth outlook was raised to mid-single digits following strong Latin America sales growth of 13.7%.

πŸ“Š Analyst sentiment favors Colgate, which has zero sell ratings compared to Clorox's two sell and two strong sell ratings.

🏦 Clorox carries $7.542B in total liabilities against only $252M in shareholders' equity following the GOJO acquisition.

Bullish Signals
  • Colgate-Palmolive generated $3.6B in free cash flow during fiscal 2025, demonstrating strong liquidity for shareholder returns.
  • The company has increased its dividend payout for 63 consecutive years, qualifying it as a Dividend Aristocrat with a proven track record.
  • Colgate raised its Base Business EPS growth outlook to mid-single digits following robust sales growth in Latin America of 13.7%.
  • The company maintains a lower beta of 0.322, indicating less stock price volatility compared to peers like Clorox.
Risk Factors
  • While the article primarily discusses Clorox's risks, it notes that Colgate-Palmolive has a significantly lower yield of 2.27% compared to Clorox's 5.89%, which may be less attractive for pure income seekers.
  • The company does not have any analyst sell ratings, but the article implies that its lower yield and higher valuation multiple (21x forward earnings vs Clorox's 15x) might limit upside potential compared to cheaper alternatives.
Full Analysis
This article compares Clorox (CLX) and Colgate-Palmolive (CL) as income stocks, concluding that while Clorox offers a higher yield of 5.89%, its financial health is deteriorating. The stock has fallen 22% over the past year, and management admits the current dividend payout is 'elevated' relative to earnings and cash flow. Clorox faces significant headwinds including a 38% drop in operating cash flow, a sharp decline in gross margins to 41.3%, and substantial debt liabilities of $7.542B following the GOJO/Purell acquisition. Management expects inflation costs to exceed $200 million in fiscal 2027, creating pressure on future dividend sustainability. In contrast, Colgate-Palmolive is presented as a safer retirement core with a 63-year track record of dividend increases and robust cash generation of $3.6B in free cash flow for 2025. The company has raised its Base Business EPS outlook to mid-single digits and maintains a lower beta, making it the preferred choice for investors prioritizing stability over high yield.